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Much of the attention focused on stem cells relates to their use in cell replacement therapy; however, 
stem cells may also transform the way in which therapeutics are discovered and validated.Introduction
The attrition rate of drugs is staggeringly 
high: more than 90% of the drugs tested 
in clinical trials fail to be approved. This 
places a significant burden on the health 
care system. Famously, compounds 
fail late in clinical testing or even after 
approval either because of a lack of suf-
ficient efficacy or unanticipated toxicity; 
many more compounds fail early in the 
discovery process. How much of this 
inefficient and expensive pharmaceutical 
pipeline problem can be rectified by hav-
ing disease models that will more faithfully 
represent the actual human diseases so 
that underlying mechanisms can be better 
understood and effective and safe medi-
cines derived and validated? In principle, 
human embryonic stem (ES) cells can be 
used for just that purpose. ES cells can 
be derived from patients with specific dis-
eases and protocols can be established 
to direct the disease-specific ES cells to 
become the very types of cells affected in 
the disease. Such disease-relevant cells 
should be able to drive more predictive 
drug discovery and toxicity studies.
Reprogramming (Dedifferentiation) 
Screens
There are many ways in which human ES 
cells or the progenitor cells generated 
from them can be used in drug screen-
ing (Figure 1). The first step is isolation of 
ES cells, which is straightforward in the 
case of the mouse but has been difficult 
and controversial for human cells. Viable 
techniques for deriving human ES cells 
include somatic cell nuclear transfer from 
human skin biopsies and using embryos 
from preimplantation genetic diagnosis. 
However, the recent creation of induced 
pluripotent stem (iPS) cells has made the 
production of human ES cells much sim-pler (Takahashi et al., 2007; see Review by 
R. Jaenisch and R. Young in this issue), 
and it is now seemingly quite feasible to 
make ES cell lines from large numbers of 
patients with particular diseases. From a 
screening perspective, lingering concerns 
over the use of oncogenes and viral vec-
tors to produce the iPS cells will undoubt-
edly mean that replacement factors will 
be sought, either small molecules or pro-
teins that can fully or partially reprogram 
differentiated human cells.
There is a considerable body of 
research on dedifferentiation (which can 
be viewed as partial reprogramming of 
adult cells) primarily in urodele amphib-
ians, which have the ability to regenerate 
limbs through blastema formation at the 
site of injury (K.D. Birnbaum and A. Sán-
chez Alvarado in this issue of Cell). This 
occurs, in part, by cellularization, that is, 
the fission of multinucleated myotubes 
into multipotential mononucleated cells 
(Duckmanton et al., 2005). Understanding 
dedifferentiation mechanisms in amphib-
ians might help in designing screens to 
reprogram adult mammalian cells. For 
example, screening a library contain-
ing tens of thousands of diverse com-
pounds culminated in the identification 
of a microtubule-disrupting molecule, 
now known as myoseverin (Rosania et 
al., 2000). This molecule causes mouse 
C2C12 myotubes to fragment into single 
cells that apparently continue to retain 
some of the differentiated properties of 
the parent cells, such as the expression 
of myosin heavy chain (Duckmanton et 
al., 2005). A second round of screen-
ing yielded another compound, called 
reversine, which is able to reprogram the 
myoblasts to become more like mesen-
chymal stem cells with the ability to for-
ward differentiate into bone and adipose Cell 13Figure 1. Stem Cell-Based Screening Assays
The goal is to create differentiated cells affected in 
various diseases from human ES cells and to carry 
out predictive toxicity testing and therapeutics 
research in a culture dish. The first step requires 
isolating disease-specific ES cell lines from pa-
tients by reprogramming (dedifferentiating) adult 
somatic cells using somatic cell nuclear transfer 
(SCNT), or with a cocktail of transcription factors 
to produce ES cell-like cells called iPS cells (Taka-
hashi et al., 2007). It will also be of interest to iden-
tify other proteins or small molecules that drive re-
programming of adult somatic cells. In the case of 
SMA and Huntington’s disease, disease-specific 
ES cells could be obtained from human embryos 
used for preimplantation genetic diagnosis (PGD). 
Human ES cells then need to be differentiated in 
culture into cell types that are affected in the dis-
ease of interest (for example, nigral DA neurons 
for Parkinson’s disease or medium spiny neurons 
for Huntington’s disease) or that are relevant for 
toxicity testing (cardiac cells and hepatocytes). 
Driving ES cell differentiation will also be required 
to produce cells that can be used therapeutically 
in cell replacement therapy (for example, pancre-
atic β cells for treating type I diabetes). The dif-
ferentiation screens themselves may also produce 
therapeutic candidates that modulate pathways 
involved in disease (Hedgehog, Wnt, BMP, etc.) or 
compounds that modulate cell proliferation.2, February 22, 2008 ©2008 Elsevier Inc. 549
cells. Interestingly, additional chemical 
modification and affinity chromatography 
with immobilized compounds suggested 
that reversine might have more than one 
essential intracellular target, including the 
structurally dissimilar MEK1 kinase and 
nonmuscle myosin II heavy chain (Chen 
et al., 2007). A self-renewal screen carried 
out with mouse ES cells by the same lab 
produced a hit, SC1, which also seemed 
to have the unusual property of binding to 
two structurally different intracellular tar-
gets (Chen et al., 2006). It will be impor-
tant to understand whether the success 
of these screens actually depends on 
having library compounds that are not 
absolutely specific for single targets.
Differentiation Screens
Directed Differentiation
Dedifferentiation or reprogramming 
screens start with differentiated cells 
and attempt to identify factors that make 
them less differentiated. However, one of 
the greatest challenges in creating large 
numbers of different kinds of disease-
relevant cells is controlling differentia-
tion, that is, inducing stem or progenitor 
cells to become more differentiated. The 
stem cell literature has many descriptions 
of “home run” experiments in which ES 
cells were treated with a concoction of 
factors, with the hope that large numbers 
of cells would undergo multiple steps of 
differentiation to produce the desired 
end product. Recently, research has 
focused on the more rational approach 
of inducing cells to undergo sequential 
stages of differentiation in a tissue cul-
ture environment, thereby recapitulating 
aspects of normal embryonic develop-
ment (see Review by C.E. Murry and G. 
Keller in this issue). For example, working 
on mouse spinal cord development, Tom 
Jessell’s group and others (reviewed in 
Briscoe and Ericson, 2001) showed 
that specification of neural cells during 
development was achieved in stages by 
controlling the expression of particular 
sets of transcription factors in response 
to precise gradients of extracellular fac-
tors. Each type of spinal cord progeni-
tor cell that appeared was defined by a 
particular set of transcription factors. 
Wichterle et al. (2002) managed to suc-
cessfully reproduce these observations 
in cell culture. They used mouse ES 
cells, expressing green fluorescent pro-550 Cell 132, February 22, 2008 ©2008 Elsevtein (GFP) under the control of a motor 
neuron-specific promoter, and grew 
them as embryoid bodies (EBs). When 
the EBs were treated with two factors 
known to be important in motor neuron 
development, first retinoic acid and then 
with an activator of sonic Hedgehog sig-
naling (Frank-Kamenetsky et al., 2002), 
functional motor neurons that expressed 
GFP appeared.
Numerous groups have tried to carry 
out equivalent studies, starting with ES 
cells or progenitor cells. For example, 
the laboratories of McKay (Lee et al., 
2000), Sasai (Watanabe et al., 2005), 
and Studer (Perrier et al., 2004) have 
used biologically relevant combinations 
of soluble factors or cell lines producing 
those factors with reasonable success. 
However, this systematic approach has 
not always worked. Andersson et al. 
(2006) were unable to derive midbrain 
dopaminergic (DA) neurons from mouse 
ES cells although they essentially fol-
lowed the Wichterle et al. protocol 
(modified to include FGF8, an essential 
inducer of differentiation along the DA 
neuronal lineage). Importantly, they were 
able to produce these cells by transiently 
expressing the homeobox transcription 
factor Lmx1a in mouse ES cells and then 
adding the relevant extracellular factors.
The key issue is how to find a gen-
eral approach for directing ES cell dif-
ferentiation. Certainly, it makes sense 
to reproduce the steps in the process 
of making a fully differentiated cell, 
with each step along the differentia-
tion pathway achieved using a sepa-
rate chemical screen. So, for example, 
mouse ES cells could be differentiated 
into DA neurons by biasing them first 
toward a neural progenitor fate (Sox2+), 
then early DA neural progenitor (Raldh+, 
Otx2+), followed by late DA neuron pro-
genitor (Lmx1a+, Nurr1+), and finally DA 
neuron (TH+, AADC+). Or, ES cells could 
be directed to become pancreatic β 
cells with initial endodermal induction 
(Sox17+), then early pancreas (Pdx-1+), 
pancreatic endocrine (Ngn3+), and then 
mature β cells secreting insulin (insu-
lin+). What is required is knowledge of 
the set of transcription factors or other 
cell-specific markers for each stage of 
development and a way of identifying 
molecules that will stimulate each step 
of the differentiation process.ier Inc.Directed Differentiation with Small 
Molecules
This type of sequential differentiation 
model has not yet been carried out from 
beginning to end. In other words, no one 
has yet used a series of screens to identify 
sets of small molecules (for example) that 
will generate fully differentiated cells from 
ES cells with high efficiency. However, 
various labs have identified factors that 
stimulate at least partial differentiation. For 
example, Ding et al. (2003) used mouse 
P19 embryonal carcinoma cells expressing 
tubulin α1-luciferase as a reporter of neu-
ral differentiation to screen a large library 
of diverse small molecules. There was 
one hit, a pyrrolopyrimidine, and analogs 
of this molecule were prepared; a more 
active compound, TSW119, was identi-
fied and an effective affinity ligand synthe-
sized. This culminated in the identification 
of GSK-3β as a specific binding partner for 
this class of neuron-inducing molecule. 
Of course, it could easily be the case that 
TSW119 inhibits other kinases and it is 
those other kinases, or perhaps GSK-3β 
in combination with one or more other 
kinases, that regulate the appearance of 
neural cells. However, given that GSK-3β 
is a well-known negative regulator of Wnt 
signaling, this result raises the possibility 
that the Wnt pathway, which is one (but not 
the only) regulator of GSK-3β activity, con-
trols neural differentiation. Several studies 
have implicated the Wnt signaling pathway 
in aspects of self-renewal and differentia-
tion, not always with consistent results (for 
instance, see Sato et al., 2004).
A number of conceptually similar 
screens have been prosecuted. For 
example, a diverse library of 100,000 
compounds was screened against P19 
embryonal carcinoma cells expressing 
luciferase downstream of the atrial natri-
uretic factor promoter to look for inducers 
of cardiac myocytes (Wu et al., 2004a). A 
diaminopyrimidine, cardiogenol, scored 
in this screen and was shown to induce 
expression of multiple markers of the 
cardiac lineage. The target of this small 
molecule has not yet been identified. A 
bone differentiation screen of a small 
molecule diversity library looked for 
increased alkaline phosphatase activity 
in multipotent 10T1/2 fibroblasts. This 
was followed by chemistry to produce 
analogs of the hits in the screen, yield-
ing a molecule termed purmorphamine 
(Wu et al., 2002) that was shown subse-
quently to be a Hedgehog pathway ago-
nist (Wu et al., 2004b).
These screens all involve fairly large-
scale testing of small molecule diversity 
libraries and use enzyme reporter read-
outs. The compound collections resemble 
those commonly used by pharmaceutical 
companies. Although these and similar 
studies have provided useful reagents and 
observations, hits from these compound 
screens often do not provide immediate 
information relating to compound target 
or mechanism of action, and so follow-up 
chemistry is required. This presents a 
problem for many investigators who have 
access neither to high-quality diversity 
sets nor to the type of chemistry expertise 
that may be needed to pursue hits from 
the primary screens.
Other types of compound libraries can 
be considered for finding molecules that 
induce cell differentiation. For example, 
many academic labs have taken to screen-
ing so-called “bioactive” collections 
comprised mainly of known drugs and 
pharmacologically active agents. These 
small sets of 1500–5000 compounds 
have become widely used for several rea-
sons. One is the relatively new interest in 
repurposing drugs (finding new uses for 
old drugs) among academic groups inter-
ested in translational research because 
this can accelerate the identification of 
therapeutics for orphan diseases (see, 
for example, North et al., 2007). However, 
there are other advantages to using these 
libraries for differentiation screens. The 
collections are readily available and, under 
favorable circumstances, hits may provide 
useful reagents for inducing cell differen-
tiation in the laboratory without the need 
for further chemistry. In addition, classes 
of molecules that induce a specific dif-
ferentiation step may provide mechanistic 
information. For example, if a number of 
different calcium channel blockers score 
in a particular cell differentiation assay, this 
would suggest several avenues of addi-
tional experimentation. Saxe et al. (2007) 
screened bioactives in a neurogenesis 
assay, starting with primary neurospheres 
prepared from embryonic rat brain and 
using a chemiluminescence assay to mea-
sure compounds that increased the total 
amount of βIII tubulin, a neuronal marker. 
One hit was the orphan ligand L-serine-
O-phosphate, which may stimulate differ-entiation by binding to metabotropic glu-
tamate receptors. Diamandis et al. (2007) 
tested a somewhat different small collec-
tion of bioactives searching for inhibitors 
of neural stem cell proliferation, which they 
detected, again indirectly, using a standard 
MTT assay. These investigators observed 
that agonists and antagonists of several 
different neurotransmitter receptors were 
antiproliferative agents (and, interestingly, 
exerted similar antimitotic effects on brain 
tumor stem cells).
Another set of “perturbagens” worthy 
of consideration for differentiation assays 
include morphogens or other protein 
inducers and substrate- or cell-associated 
factors. Embryonic development is regu-
lated largely by a small number of ligand-
activated signaling pathways, including 
those of TGF-β/BMP, FGF, Wnt, Notch, 
and Hedgehog. Investigators developing 
small-scale (nonrobotic) differentiation pro-
tocols usually test several of these protein 
factors, whereas those designing robotic 
screening protocols routinely focus on 
small molecules and not on proteins. This 
is curious because, although the number 
of active signaling pathways may turn out 
to be small, the embryonic signaling envi-
ronment is defined by having each relevant 
ligand present at the correct time, in the 
proper amount, and in appropriate combi-
nations with other factors in order to have 
cell fate accurately specified. It may be 
that dialing in the correct concentrations 
and combinations of these ligands could 
increase the efficiency of cell differentia-
tion substantially. Such a problem could 
ideally be solved by robotic screening, 
which can test suitably large combinations 
of these factors.
Similarly, several investigators have 
explored growing undifferentiated cells 
on small numbers of inducer or feeder cell 
lines or on extracellular matrices to good 
effect, but only recently has attention been 
drawn to the advantages of combinatorial 
testing of substrate-associated and solu-
ble factors. Flaim et al. (2005) measured 
the effects of combinations of extracellular 
matrices (in this case, all in the same cell 
culture medium) on the ability of mouse 
ES cells to differentiate toward hepato-
cytes and found some striking differences 
among the various combinations. Soen et 
al. (2006) looked at microarrays of human 
primary neural precursor cells grown on 
substrates containing various combina-Cell 132tions of matrix components with bound 
morphogens. They also found significant 
variation in the biasing of cells toward 
neuronal or glial lineages under the differ-
ent conditions. Thus, it seems an excel-
lent idea to comprehensively probe these 
types of protein factors along with some of 
the small molecules in sequential differen-
tiation assays. Other types of assays such 
as siRNA assays or screening ORFeome 
libraries will become more popular once 
suitable reagents become available, but 
the usefulness of screening these types of 
libraries has already been demonstrated 
(Pritsker et al., 2006; Ivanova et al., 2006).
Another item worthy of discussion con-
cerns the way in which cell differentiation 
is measured. Most differentiation assays 
conducted to date have been population 
studies in that they measured the total 
amount of luciferase activity or of individ-
ual protein markers in each test well. In a 
sense, these studies are conceptually sim-
ilar to the industry standard high-through-
put assays, which are often conducted in 
cell-free form (e.g., enzyme assays) but are 
meant to accommodate the large number 
of assays and impressive number of com-
pounds that are generally tested in phar-
maceutical and biotechnology companies. 
A different approach, gaining in popular-
ity in both academia and industry, is high 
content analysis or microscope-based 
analysis. This kind of assay, which can be 
automated, provides information concern-
ing multiple properties of individual cells 
and is well suited to studies of differen-
tiation where the cell populations tend to 
be nonhomogeneous. For example, even 
weak hits in a differentiation screen can be 
detected by counting the number of indi-
vidual cells expressing a relevant marker, 
often by means of a fluorescent protein or 
antibody label. In addition, multiple mark-
ers can be used, and quantitative data on 
a per cell basis can be obtained. High con-
tent analysis also reveals whether or not 
particular compounds are toxic or induce 
changes in cell shape, such as the exten-
sion of processes from neuronal cells or 
even false positives that occur due to cell 
shrinkage. Thus, high content screening 
seems likely to play a very important role 
in attempts to regulate cell differentiation. 
Perhaps this approach, especially when 
combined with biologically or medically 
relevant cells, will provide a greater num-
ber of new therapeutics., February 22, 2008 ©2008 Elsevier Inc. 551
Disease Mechanisms and Toxicity
When it becomes possible to produce all 
differentiated cell types from mouse or 
human ES cells, many avenues of experi-
mentation become possible. For instance, 
in many diseases, certain cell types are 
affected more than others: in Spinal Mus-
cular Atrophy (SMA) and Amyotrophic 
Lateral Sclerosis (ALS), motor neurons 
degenerate; in Huntington’s disease, stri-
atal medium spiny neurons die; and in Par-
kinson’s disease, a subset of DA neurons 
in the substantia nigra are lost. However, 
even a global neurodegenerative disor-
der such as Alzheimer’s disease affects 
certain populations of cells, such as ento-
rhinal cortical neurons, more than others. 
This differential susceptibility is particu-
larly perplexing in the case of SMA and 
Huntington’s disease, which are genetic 
disorders, as all cells carry the same muta-
tion. Having access to appropriately differ-
entiated neurons should help in providing 
a more comprehensive understanding 
of the selective cell death that accompa-
nies these diseases even in cases, such 
as ALS, that are predominantly sporadic, 
rather than familial.
It is already possible to make large num-
bers of motor neurons from ES cells and 
studies of disease mechanism are under-
way. Di Giorgio et al. (2007) cultured motor 
neurons generated from mouse ES cells 
isolated from an ALS mouse model and 
showed that their rate of death is faster 
than that of ES cell-derived motor neurons 
from normal mice and that the death rate 
can be accelerated further by cocultur-
ing them with astrocytes obtained from 
the same mice. Astrocyte-induced death 
of mutant ES cell-derived motor neurons 
is readily amenable to even a large-scale 
screening campaign aimed at finding 
survival-enhancing compounds. My lab 
has isolated ES cells from a mouse SMA 
model (Sinor and L.L.R., unpublished data) 
and induced them to differentiate into large 
numbers of motor neurons and is currently 
conducting a high content screening cam-
paign to identify drugs that will prolong the 
survival of the motor neurons. Until now, 
most SMA studies have been conducted 
on fibroblasts, which are phenotypically 
normal, and it will be important to deter-
mine if screening in motor neurons pro-
duces better therapeutic candidates. The 
overall goal of this type of approach is 
to study the pathogenic mechanisms of 552 Cell 132, February 22, 2008 ©2008 Elsethese degenerative diseases in the cells 
that are actually affected in the disease.
Most pharmaceutical scientists view the 
lack of adequately predictive toxicology 
during preclinical testing as a huge prob-
lem in effective development of new drugs. 
Eliminating lead compounds with true 
hepatotoxicity and cardiotoxicity is of spe-
cial concern. The ability to derive ES cells 
from a wide and representative spectrum 
of the human population and having valid 
protocols to differentiate them into hepa-
tocytes and cardiac myocytes should pro-
vide straightforward assays for analyzing 
certain aspects of drug metabolism and 
for assessing probable side effects. A key 
question is how mature the differentiated 
cells need to be before they can faithfully 
represent their adult counterparts (see, for 
example, Khetani and Bhatia, 2007).
It is now realistic to imagine creating 
disease-specific human ES cell lines from 
large numbers of patients. Applying fun-
damental principles of developmental biol-
ogy should enable screens to be designed 
using a wide variety of ES cell-derived cell 
types at different stages of differentiation, 
allowing diseases to be modeled more 
faithfully. These stem cell-based screens 
may well provide more efficient and pre-
dictive methods for discovering and test-
ing different classes of therapeutics.
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